Document is current
Any future updates will be listed below
-
Authors
Griffin, Timothy M.
Lopes, Erika Barboza Prado
Cortassa, Dominic
Batushansky, Albert
Jeffries, Matlock A.
Makosa, Dawid
Jopkiewicz, Anita
Mehta-D’souza, Padmaja
Komaravolu, Ravi K.
Kinter, Michael T.
-
Funding
Funding for this research was provided by:
NIH Office of Research on Women’s Health (3R01AG049058-03S1)
National Institute of General Medical Sciences (R24GM137786, P20GM103447, P30GM114731)
U.S. Department of Veterans Affairs (I01BX004666, I01BX004882, BX006046, CX002494)
Oklahoma Medical Research Foundation (n/a)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R33AR078075, R01AR076440)
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 26 November 2024
First Online: 5 December 2024
Declarations
:
: The animal experiments were conducted according to protocol approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee (protocol #14–54 and #17–60).
: Not applicable.
: TMG has a patent application pending entitled, “COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR” (#18/411,242).
